Innate Pharma (IPHA)
(Delayed Data from NSDQ)
$2.46 USD
+0.09 (3.80%)
Updated Apr 24, 2024 03:59 PM ET
After-Market: $2.48 +0.02 (0.81%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.46 USD
+0.09 (3.80%)
Updated Apr 24, 2024 03:59 PM ET
After-Market: $2.48 +0.02 (0.81%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
Zacks News
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
by Zacks Equity Research
Innate Pharma (IPHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study
by Zacks Equity Research
Innate Pharma (IPHA) stock moves up in the pre-market hours as the FDA lifts the partial clinical hold placed on a study evaluating lacutamab for Sezary syndrome.
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag
by Zacks Equity Research
Innate (IPHA) and Sanofi's SAR'579 / IPH6101 get Fast Track Designation in the United States for the treatment of hematological malignancies.
Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis
by Zacks Equity Research
The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic esophagitis.
The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, InflaRx, Legrand, Innate Pharma and DiaSorin
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, InflaRx, Legrand, Innate Pharma and DiaSorin
Europe Equities Are Hot on Stimulus Optimism: 5 Picks
by Tirthankar Chakraborty
Europe stocks rally on hopes that the European Union will unveil large stimulus package to reduce the economic fallout from the coronavirus pandemic.
Company News for Jan 10, 2020
by Zacks Equity Research
Companies In The News Are:
Innate Pharma's Filing for Leukemia Drug Accepted in Europe
by Zacks Equity Research
The EMA accepts Innate's (IPHA) marketing application for Lumoxiti, developed to treat relapsed/refractory hairy cell leukemia in adult patients having received minimum two prior systemic therapies.
Company News For Jan 3, 2020
by Zacks Equity Research
Companies in the news are: CMG, SAVA, RCON, IPHA